Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

By Mariam Sunny (Reuters) -Shares of Metsera fell over 15% in early trading on Monday, after the weight-loss drug developer accepted a sweetened offer from Pfizer to end a fierce bidding war between the pharma giant and Danish rival Novo Nordisk.

Pfizer not only beat expectations last quarter, but also boosted its guidance.

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's also taking on a lot of risk.

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million in value and announced this year. M&A, however, has not been enough for what the Goldman analysts say will be a third year of underperformance vs.

The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per share (EPS) declined 18% year over year in Q3. That might seem to indicate that the company's dividend is on shakier ground. But there's more to the story.